ストックスクリーナーアプリを入手
0.291
0.27%
-0.0008
アフターアワーズ：
.30
0.009
+3.09%
前日終値:
$0.2918
開ける：
$0.29
24時間の取引高:
277.92K
Relative Volume:
0.81
時価総額：
$16.09M
収益：
$20.97M
当期純損益:
$-118.51M
株価収益率:
-0.1413
EPS:
-2.06
ネットキャッシュフロー:
$-94.45M
1週間 パフォーマンス:
+9.03%
1か月 パフォーマンス:
+5.59%
6か月 パフォーマンス:
-62.61%
1年 パフォーマンス:
-78.44%
1日の値動き範囲:
$0.281
$0.3048
1週間の範囲:
$0.26
$0.3199
52週間の値動き範囲:
$0.24
$1.40
Cara Therapeutics Inc Stock (CARA) Company Profile
名前
Cara Therapeutics Inc
セクター
電話
203-406-3700
住所
400 ATLANTIC STREET, SUITE 500, STAMFORD, CT
Cara Therapeutics Inc Stock (CARA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-03-08 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-03-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-11-01 | 再開されました | Canaccord Genuity | Buy |
| 2021-08-03 | 開始されました | JP Morgan | Neutral |
| 2020-04-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-08-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-05-29 | 繰り返されました | Laidlaw | Buy |
| 2019-02-06 | 再開されました | Jefferies | Buy |
| 2019-01-15 | 開始されました | BofA/Merrill | Neutral |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 開始されました | Jefferies | Buy |
| 2018-08-08 | 繰り返されました | Stifel | Buy |
| 2018-06-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-03-12 | 再開されました | H.C. Wainwright | Buy |
| 2018-02-12 | アップグレード | Janney | Neutral → Buy |
| 2018-01-19 | 開始されました | Seaport Global Securities | Buy |
| 2017-06-30 | ダウングレード | Janney | Buy → Neutral |
| 2017-06-30 | 繰り返されました | Laidlaw | Buy |
| 2017-06-30 | 繰り返されました | Stifel | Buy |
| 2017-03-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-03-28 | 繰り返されました | Laidlaw | Buy |
| 2017-03-10 | 繰り返されました | Laidlaw | Buy |
| 2016-10-13 | 開始されました | H.C. Wainwright | Buy |
| 2016-08-08 | 繰り返されました | Needham | Buy |
すべてを表示
Cara Therapeutics Inc (CARA) 最新ニュース
Cara Operations (TSE:CARA) Stock Price Down 2.4% – Here’s Why - Defense World
Cara Therapeutics, Inc.'s (NASDAQ:CARA) Share Price Is Matching Sentiment Around Its Revenues - Simply Wall St
Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update - Quantisnow
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
CSL Limited Reports 13.5% Stake In Cara Therapeutics - XM
Truist Financial Initiates Coverage on Amentum (NYSE:AMTM) - Defense World
América Móvil (NYSE:AMX) PT Lowered to $20.80 - Defense World
Riskified Ltd. (NYSE:RSKD) Given Consensus Recommendation of “Hold” by Analysts - Defense World
Heritage Global Inc. (NASDAQ:HGBL) Shares Acquired by Dimensional Fund Advisors LP - Defense World
Dimensional Fund Advisors LP Purchases 55,636 Shares of VirTra, Inc. (NASDAQ:VTSI) - Defense World
Renaissance Technologies LLC Reduces Position in Cara Therapeutics, Inc. (NASDAQ:CARA) - Defense World
Opioid Use Disorder (OUD) Market Report 2024: Growth, Trends, Competitive Outlook to 2033 - WhaTech
Europe Pruritus Therapeutics Market Size & Outlook, 2030 - Grand View Research
Financial Health Report: Cara Therapeutics Inc (CARA)’s Ratios Tell a Tale - The Dwinnex
What technical indicators reveal about CARA stock - US Post News
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Quantisnow
Medical Marijuana Market Report 2024Growth, Forecast In The Latest Research - WhaTech
Cara Therapeutics (NASDAQ:CARA) Receives New Coverage from Analysts at StockNews.com - Defense World
Market Recap: Cara Therapeutics Inc (CARA)’s Positive Momentum, Closing at 0.31 - The Dwinnex
Cara Therapeutics, Inc. (NASDAQ:CARA) Sees Large Increase in Short Interest - Defense World
Stock Analysts’ New Coverage for September 26th (AINC, AIRI, APTO, BLK, CARA, CBOE, CLLS, CME, CMLS, CTLT) - Defense World
G-Protein Coupled Receptors Market Growth Analysis, Trends, Share, Market Size And Forecast To 2033 - WhaTech
A closer look at Cara Therapeutics Inc (CARA) is warranted - US Post News
WesBanco, Inc. (NASDAQ:WSBC) Receives Consensus Rating of “Hold” from Analysts - Defense World
Pruritus Clinical Trials 2024: FDA Approvals, Medication, - openPR
Ra capital executives buy Bicara Therapeutics shares for $32.99m By Investing.com - Investing.com Canada
Aclaris Therapeutics neutral rating reiterated on phase 2a trial - Investing.com
Federated Hermes Inc. Acquires Shares of 670,468 Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Carmat launches capital increase, stock plummets - Marketscreener.com
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSAGE - PR Newswire
Most Promising New Drugs for Hidradenitis Suppurativa, with Raj Chovatiya, MD, PhD - MD Magazine
The time has not yet come to remove your chips from the table: Cara Therapeutics Inc (CARA) - SETE News
Cara Therapeutics Inc (CARA)’s Day in Review: Closing at 0.26, Down by -2.85 - The Dwinnex
CARA’s Stock Market Adventure: -62.18% YTD Growth Amidst Volatility - The InvestChronicle
How to interpret Cara Therapeutics Inc (CARA)’s stock chart patterns - US Post News
Pruritus Therapeutics Market Competition & Segment Analysis – Actavis Plc, Amgen Inc., Bristol-Myers Squibb, Cara Therapeutics, Cipla – Cauverynews - Cauverynews
Metric Deep Dive: Understanding Cara Therapeutics Inc (CARA) Through its Ratios - The Dwinnex
Pruritus Pipeline Analysis 2024: FDA Approvals and Emerging - openPR
Does Cara Therapeutics Inc (CARA) offer a good opportunity for investors? - SETE News
Cara Therapeutics (NASDAQ:CARA) Now Covered by Analysts at StockNews.com - Defense World
Following more layoffs, Stamford’s Cara Therapeutics considers ‘strategic alternatives,’ including dissolving company - Hartford Business Journal
Analysts review Cara Therapeutics Inc’s rating - Knox Daily
Cara Therapeutics, Inc. (NASDAQ:CARA) Given Consensus Rating of “Hold” by Brokerages - Defense World
Vanguard Group Inc. Reduces Position in Cara Therapeutics, Inc. (NASDAQ:CARA) - Defense World
CARA Stock Earnings: Cara Therapeutics Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace
Cara Therapeutics (NASDAQ:CARA) Coverage Initiated by Analysts at StockNews.com - Defense World
Cara Therapeutics (NASDAQ:CARA) Issues Quarterly Earnings Results, Misses Estimates By $0.10 EPS - Defense World
Cara: Q2 Earnings Snapshot - San Antonio Express-News
Investing in Cara Therapeutics Inc (CARA) Is Getting More Attractive - Knox Daily
Understanding the Risks of Investing in Gain Therapeutics Inc (GANX) - Knox Daily
Cara Therapeutics receives Nasdaq compliance extension - Investing.com India
Cara Therapeutics Inc (CARA) 財務データ
収益
当期純利益
現金流量
EPS
Cara Therapeutics Inc (CARA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Posner Christopher | PRESIDENT AND CEO |
May 02 '24 |
Sale |
0.75 |
3,936 |
2,952 |
176,585 |
| Goncalves Joana | CHIEF MEDICAL OFFICER |
Apr 05 '24 |
Sale |
0.83 |
2,753 |
2,285 |
53,365 |
| Terrillion Scott | SEC'Y; CHIEF COMPLIANCE & G.C. |
Apr 05 '24 |
Sale |
0.83 |
2,753 |
2,285 |
88,247 |
| Terrillion Scott | SEC'Y; CHIEF COMPLIANCE & G.C. |
Feb 29 '24 |
Sale |
0.89 |
3,293 |
2,931 |
91,000 |
| Posner Christopher | PRESIDENT AND CEO |
Feb 29 '24 |
Sale |
0.89 |
5,834 |
5,192 |
180,521 |
| Goncalves Joana | CHIEF MEDICAL OFFICER |
Feb 29 '24 |
Sale |
0.89 |
3,293 |
2,931 |
56,118 |
| Posner Christopher | PRESIDENT AND CEO |
Feb 08 '24 |
Sale |
0.53 |
35,575 |
18,855 |
186,355 |
| Posner Christopher | PRESIDENT AND CEO |
Feb 01 '24 |
Sale |
0.55 |
4,981 |
2,740 |
221,930 |
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):